PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 8, 20260 citationsOpen Access

Dynamic Medicine — Part V Clinical Trials in a Dynamic Disease World Why Linear Randomization Fails to Capture Instability, Timing, and Bias

View Full Paper
ADAnita DomargårdKarolinska University Hospital

Key Points

  • This research addresses how conventional clinical trial designs fail to accommodate the dynamic nature of diseases, focusing on timing and biases.
  • Examines clinical trial structures and their assumptions about disease stability.
  • Analyzes concepts from complex systems science related to disease dynamics.
  • Proposes an alternative framework for trial design that includes instability and temporal factors.
  • Identifies significant limitations in static trial designs when applied to dynamic disease contexts.
  • Highlights the need for considering timing and system phases to accurately capture treatment effects.
  • Suggests that improved trial designs could enhance the reliability of AI systems trained on clinical data.

Abstract

This paper examines a structural limitation in modern clinical trial design: the mismatch between dynamic disease processes and largely static experimental frameworks. While randomized controlled trials remain the cornerstone of evidence-based medicine, most trial architectures assume relatively stable disease states and phase-insensitive treatment allocation. Drawing on concepts from complex systems science and the Universal Resonance Model (URM), the paper argues that many clinically important events—such as inflammatory flares, sepsis, and acute systemic deterioration—represent rapid system transitions rather than steady disease states. Under such conditions, baseline randomization and fixed endpoints may obscure timing-dependent treatment effects. The article therefore proposes that instability, system phase, and temporal dynamics should become explicit considerations in future trial design. Recognizing disease as a dynamic process may improve both evidence generation and the safety of AI systems trained on clinical trial data.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Anita Domargård (2026) studied this question.

synapsesocial.com/papers/69ada8dfbc08abd80d5bc44chttps://doi.org/10.5281/zenodo.18902451
Ask AI
Helpful
Bookmark
Share
View Full Paper